Session Detail

Session Title: Pathway-Targeted Therapeutics: Coming of Age
Session Type: Plenary Session
Session Start/End Time: Wednesday, Apr 04, 2012, 8:00 AM -10:00 AM
Location: McCormick Place South (Level 1), Room S100 (Grand Ballroom)
CME: CME-Designated
CME/CE Hours: 2
Session Description: Therapies targeting oncogenic signaling pathways continue to mature, with many new drug approvals within the past year. Speakers in this session will highlight several recent examples including the BRAF inhibitor vemurafenib, the ALK inhibitor crizotinib, and the antiandrogen MDV3100. The clinical success of targeted agents requires precise identification of the responder population, typically through profiling of tumor genomes, and consideration of appropriate combination therapies to maximize response and curtail the emergence of drug resistance. These concepts will be discussed in the context of different tumor types and drug targets that are central concerns in clinical oncology.
Charles L. Sawyers. Mem. Sloan-Kettering Cancer Ctr., New York, NY
PL04-03: Cell signaling by receptor tyrosine kinases: From basic principles to cancer therapy
Wednesday, Apr 04, 2012, 8:00 AM - 8:30 AM
Joseph Schlessinger. Yale Univ. School of Medicine, New Haven, CT
PL04-02: Ras and Raf signaling: From biology to therapeutics
Wednesday, Apr 04, 2012, 8:30 AM - 9:00 AM
Richard M. Marais. The Paterson Institute for Cancer Research, Manchester, United Kingdom
ALK in non-small cell lung cancer: Understanding sensitivity and resistance to ALK inhibition
Wednesday, Apr 04, 2012, 9:00 AM - 9:30 AM
Alice T. Shaw. Massachusetts General Hospital and Harvard Medical School, Boston, MA
PL04-01: Overcoming cancer drug resistance
Wednesday, Apr 04, 2012, 9:30 AM -10:00 AM
Charles L. Sawyers. Mem. Sloan-Kettering Cancer Ctr., New York, NY